Design and validation of a consistent and reproducible manufacture process for the production of clinical-grade bone marrow–derived multipotent mesenchymal stromal cells

Margarita Codinach, Margarita Blanco, Isabel Ortega, Mireia Lloret, Laura Reales, Maria Isabel Coca, Sílvia Torrents, Manel Doral, Irene Oliver-Vila, Miriam Requena-Montero, Joaquim Vives, Joan Garcia-López

Research output: Contribution to journalArticleResearchpeer-review

22 Citations (Scopus)

Abstract

© 2016 International Society for Cellular Therapy Background Multipotent mesenchymal stromal cells (MSC) have achieved a notable prominence in the field of regenerative medicine, despite the lack of common standards in the production processes and suitable quality controls compatible with Good Manufacturing Practice (GMP). Herein we describe the design of a bioprocess for bone marrow (BM)–derived MSC isolation and expansion, its validation and production of 48 consecutive batches for clinical use. Methods BM samples were collected from the iliac crest of patients for autologous therapy. Manufacturing procedures included: (i) isolation of nucleated cells (NC) by automated density-gradient centrifugation and plating; (ii) trypsinization and expansion of secondary cultures; and (iii) harvest and formulation of a suspension containing 40 ± 10 × 106 viable cells. Quality controls were defined as: (i) cell count and viability assessment; (ii) immunophenotype; and (iii) sterility tests, Mycoplasma detection, endotoxin test and Gram staining. Results A 3-week manufacturing bioprocess was first designed and then validated in 3 consecutive mock productions, prior to producing 48 batches of BM-MSC for clinical use. Validation included the assessment of MSC identity and genetic stability. Regarding production, 139.0 ± 17.8 mL of BM containing 2.53 ± 0.92 × 109 viable NC were used as starting material, yielding 38.8 ± 5.3 × 106 viable cells in the final product. Surface antigen expression was consistent with the expected phenotype for MSC, displaying high levels of CD73, CD90 and CD105, lack of expression of CD31 and CD45 and low levels of HLA-DR. Tests for sterility, Mycoplasma, Gram staining and endotoxin had negative results in all cases. Discussion Herein we demonstrated the establishment of a feasible, consistent and reproducible bioprocess for the production of safe BM-derived MSC for clinical use.
Original languageEnglish
Pages (from-to)1197-1208
JournalCytotherapy
Volume18
Issue number9
DOIs
Publication statusPublished - 1 Sep 2016

Keywords

  • advanced therapy medicinal product
  • bone marrow
  • cell culture
  • clinical-grade manufacture
  • Good Manufacturing Practice
  • inactivated human serum
  • multipotent mesenchymal stromal cell
  • process validation

Fingerprint Dive into the research topics of 'Design and validation of a consistent and reproducible manufacture process for the production of clinical-grade bone marrow–derived multipotent mesenchymal stromal cells'. Together they form a unique fingerprint.

Cite this